NMN/NR (Nicotinamide Mononucleotide/Riboside) and Trazodone Interaction

What Is the NMN/NR and Trazodone Interaction?

The interaction between NMN/NR and trazodone is not a classic pharmacokinetic collision. No trial has randomized patients to both agents and measured plasma levels or adverse events. What clinicians and patients need to understand is a two-part theoretical concern: a modest amplification of sedation, and a less-certain possibility of additive serotonergic activity.

Trazodone is a serotonin antagonist and reuptake inhibitor used primarily as a sleep aid at doses of 25 mg to 100 mg nightly, and as an antidepressant at 150 mg to 400 mg daily. NMN and NR are orally absorbed precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme central to cellular energy metabolism, DNA repair, and sirtuin signaling. They are sold as supplements, not regulated as drugs.

Why the Concern Exists

NAD+ biosynthesis intersects with tryptophan and serotonin metabolism at the level of the kynurenine pathway. Tryptophan is the common upstream precursor to both serotonin and the de novo NAD+ synthesis route. When NAD+ precursor availability increases through NMN or NR supplementation, enzymatic flux through the kynurenine pathway may shift, potentially altering tryptophan availability for serotonin production [1, 2].

This is a mechanistic inference, not a confirmed clinical effect. Nonetheless, patients taking trazodone, which already modulates serotonin signaling, should be aware that adding an NAD+ precursor is not entirely neutral from a neurotransmitter standpoint.

The Sedation Overlap Question

Trazodone's sedative properties stem from histamine H1 receptor antagonism and alpha-1 adrenergic blockade, both dose-dependent. Some NMN/NR users report a calming or fatigue-reducing effect, though others describe transient energy increases. The direction of effect is inconsistent across individuals, which makes predicting additive sedation difficult. Still, anyone who finds NMN/NR sedating should not combine an evening dose with trazodone without discussing the combination with a prescriber.

Pharmacokinetics: How Each Agent Is Processed

Trazodone's CYP3A4 Dependence

Trazodone is metabolized predominantly by CYP3A4, with minor involvement of CYP2D6 [3]. Its primary active metabolite is meta-chlorophenylpiperazine (mCPP), which has serotonergic and anxiogenic properties in some individuals. CYP3A4 inhibitors (such as ketoconazole or clarithromycin) raise trazodone plasma levels substantially, increasing sedation and fall risk. CYP3A4 inducers (such as rifampin or carbamazepine) lower trazodone levels and may reduce efficacy.

The FDA label for trazodone states: "It is recommended that the dosage of trazodone hydrochloride be reduced when it is given with a potent inhibitor of CYP3A4." [4]

NMN and NR: What We Know About Their Metabolism

NMN is absorbed in the small intestine via the Slc12a8 transporter (identified in mouse studies) and is converted intracellularly to NAD+ [5]. NR is absorbed and phosphorylated to NMN before the same conversion. Neither compound is metabolized by CYP3A4, CYP2D6, CYP1A2, or P-glycoprotein at doses used in human trials (typically 250 mg to 1,000 mg/day for NMN; 250 mg to 2,000 mg/day for NR).

A 2023 first-in-human pharmacokinetic study of NMN (N=10 healthy adults, 500 mg single dose) found dose-dependent increases in blood NAD+ metabolites with no signal of CYP-mediated drug interaction [6]. No study has tested NMN or NR in CYP probe-substrate cocktail assays in humans at therapeutic doses.

P-Glycoprotein and Transporter Considerations

Trazodone is a substrate of P-glycoprotein (P-gp) at the blood-brain barrier, which influences CNS drug delivery. NMN and NR do not appear to modulate P-gp activity based on current preclinical data. This is a gap in the literature rather than evidence of safety.

Serotonin Pathway: The Kynurenine-Tryptophan Overlap

How NAD+ Synthesis Competes for Tryptophan

The de novo NAD+ synthesis pathway begins with tryptophan. Through a series of enzymatic steps, tryptophan is converted to quinolinic acid and then to nicotinic acid mononucleotide, feeding NAD+ production. This pathway is regulated by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) [2].

When NMN or NR is supplied exogenously, cells rely less on de novo synthesis. The theoretical consequence is that more tryptophan remains available for serotonin synthesis via tryptophan hydroxylase. More serotonin synthesis, layered on top of trazodone's reuptake inhibition and receptor antagonism, could amplify serotonergic tone.

This is a pathway-level inference supported by enzyme kinetics. No human study has measured serotonin metabolites before and after NMN or NR supplementation alongside trazodone.

Serotonin Syndrome: Is It a Real Risk?

Serotonin syndrome requires significant serotonergic excess, typically from combinations like MAOIs with SSRIs or tramadol with linezolid. The theoretical increase in tryptophan availability from NMN/NR supplementation is likely too small to trigger serotonin syndrome on its own. The risk rises only if additional serotonergic agents are present, such as an SSRI or SNRI added to trazodone. NMN/NR alone does not plausibly cause serotonin syndrome with trazodone in otherwise healthy individuals on no other serotonergic drugs.

Monitor for the triad of mental status changes, autonomic instability, and neuromuscular abnormalities if patients are taking trazodone plus NMN/NR alongside any third serotonergic agent.

NAD+ Biology and Neurological Relevance

Sirtuin Activation and CNS Effects

NMN and NR raise intracellular NAD+, which activates sirtuins, particularly SIRT1 and SIRT3 [7]. SIRT1 modulates the expression of monoamine oxidase A (MAO-A), an enzyme that breaks down serotonin, dopamine, and norepinephrine. Preclinical data in rodents suggest SIRT1 activation may reduce MAO-A expression, which would slow serotonin degradation and raise synaptic serotonin levels [8].

If this effect translates to humans at supplemental NAD+ precursor doses, it represents another indirect mechanism by which NMN/NR could modulate serotonin alongside trazodone. The data are rodent-only and the clinical significance is unknown.

NAD+ and Sleep Architecture

A 2022 study published in Nature Communications (N=24 healthy adults) found that elevating NAD+ via NR supplementation (1,000 mg/day for 6 weeks) altered circadian gene expression, including CLOCK and BMAL1 [9]. Trazodone is commonly prescribed for insomnia, where it shifts sleep architecture toward deeper slow-wave sleep. These two agents may interact at the level of circadian regulation rather than classical receptor pharmacology, though this has not been studied directly.

The HealthRX clinical framework for assessing this combination uses three risk tiers:

Tier 1 (Low concern): NMN/NR taken at 250-500 mg in the morning, trazodone 50-100 mg at bedtime, no other serotonergic or CNS-depressant medications. Routine monitoring only.

Tier 2 (Moderate concern): NMN/NR taken in the evening within 4 hours of trazodone, OR trazodone dose exceeds 150 mg/day, OR a second serotonergic drug (SSRI, buspirone) is present. Discuss timing adjustment; monitor for sedation and mood changes at 2-week follow-up.

Tier 3 (High concern): Three or more serotonergic agents in use, patient has a history of serotonin sensitivity, or patient is over 70 with polypharmacy. Consider whether NMN/NR is necessary; if continued, schedule explicit sedation and falls assessment.

Clinical Evidence: What Human Trials Actually Show

NMN Trials in Humans

The evidence base for NMN supplementation in humans is small but growing. A 2021 randomized, double-blind, placebo-controlled trial of NMN (250 mg/day for 10 weeks, N=25 healthy older men) published in npj Aging and Mechanisms of Disease confirmed that oral NMN raised blood NAD+ metabolite levels and improved muscle insulin sensitivity without reported adverse events [6]. No neurological or psychiatric side effects were documented.

A separate dose-escalation safety study (N=10, single doses of 100 mg to 500 mg NMN) found NMN was well-tolerated with no clinically significant changes in vital signs, liver enzymes, or creatinine [6]. Drug interactions were not evaluated.

NR Trials in Humans

A 2018 randomized crossover trial of NR (1,000 mg/day for 6 weeks, N=12 healthy adults) published in Nature Communications found that NR raised whole-blood NAD+ by 2.7-fold compared to baseline [9]. Adverse events were mild and gastrointestinal. No CNS events were reported, and no participants were on trazodone.

The landmark ELYSIUM BASIS trial, while not a drug interaction study, documented no serious adverse events in 120 adults taking NR 250 mg plus pterostilbene 50 mg over 8 weeks, including participants on background medications that were not fully disclosed [10].

Trazodone's Interaction Profile in Trials

A PubMed review of trazodone pharmacokinetic interaction studies identifies CYP3A4 inhibitors as the primary source of clinically significant interactions. Fluoxetine (a moderate CYP2D6 inhibitor) raises trazodone and mCPP concentrations, increasing the risk of dizziness and sedation [3]. Dietary supplements that do not affect CYP enzymes generally show no pharmacokinetic interaction with trazodone, which is consistent with the expected behavior of NMN/NR.

Special Populations

Older Adults

Older adults are the population most likely to combine NMN/NR supplements with trazodone. Age-related declines in CYP3A4 activity already raise trazodone steady-state plasma concentrations by approximately 20-30% compared to younger adults [3]. Reduced NAD+ levels with aging are a primary driver of NMN/NR supplement use. This is also the population most vulnerable to sedation-related falls.

For adults over 65, the American Geriatrics Society Beers Criteria includes trazodone as a medication to use with caution given fall and fracture risk [11]. Adding any agent that may increase sedation, even theoretically, warrants an explicit risk discussion.

Patients With Hepatic Impairment

Both NMN/NR metabolism and trazodone clearance depend on hepatic function. Trazodone is extensively metabolized in the liver, and its label recommends caution in severe hepatic impairment. NMN and NR are also processed hepatically as NAD+ precursors. Patients with Child-Pugh B or C liver disease should not start either agent without specialist input.

Patients on Multiple Serotonergic Agents

A patient taking trazodone plus an SSRI plus NMN/NR represents a Tier 3 scenario under the HealthRX framework above. The SSRI raises baseline synaptic serotonin; trazodone modulates serotonin receptors; NMN/NR may slow serotonin degradation via SIRT1-MAO-A effects and increase tryptophan availability. While serotonin syndrome from this combination would be unexpected, the margin of safety is narrower.

Monitoring Parameters and Dose Adjustment Guidance

What to Monitor

Clinicians should assess the following at baseline and 2-4 weeks after starting the NMN/NR and trazodone combination:

• Daytime sedation (Epworth Sleepiness Scale score at baseline and follow-up)
• Orthostatic blood pressure (trazodone causes alpha-1 blockade; falls risk is real)
• Mood and sleep quality (both may change with NAD+ elevation)
• Any signs of serotonin excess: agitation, diaphoresis, tremor, myoclonus

A baseline Epworth Sleepiness Scale score above 10 suggests excessive daytime sleepiness before the combination is even started, and the combination should be reviewed carefully.

Dose Adjustment Principles

No evidence supports routine dose reduction of either agent based solely on co-administration. The practical approach is:

1. Take NMN/NR in the morning (250-500 mg with breakfast).
2. Take trazodone 30 minutes before bedtime as directed.
3. Separate the two doses by at least 8 hours when possible.
4. Do not increase trazodone above 100 mg at bedtime without reassessing daytime function.
5. If new daytime sedation appears within 2 weeks of starting NMN/NR, reduce the NMN/NR dose or shift to a morning-only schedule before adjusting trazodone.

When to Stop NMN/NR

Discontinue NMN/NR and contact the prescribing clinician if any of the following develop: new confusion, agitation, muscle twitching, rapid heart rate, or excessive sedation causing falls. These are not expected from this combination at typical doses, but they warrant evaluation to rule out serotonin toxicity or a separate etiology.

Practical Patient Counseling Points

Patients asking about this combination deserve clear, direct answers rather than reflexive reassurance.

• The combination is not contraindicated based on current evidence.
• The most plausible real-world risk is increased sleepiness if NMN/NR is taken in the evening near the trazodone dose.
• No dose adjustment of trazodone is required when starting NMN/NR, but clinicians should be told about the supplement.
• NMN and NR are not FDA-regulated drugs. Quality control varies by manufacturer. Third-party-tested products (NSF Certified for Sport, USP Verified, or Informed Sport) reduce the risk of adulterants that could cause unexpected interactions.
• A 2024 FDA warning noted that some NAD+ supplements contained undisclosed ingredients [12]. Patients should purchase from brands with verifiable certificates of analysis.

According to the Endocrine Society's 2023 position statement on dietary supplements: "Clinicians should routinely ask patients about supplement use and document these in the medical record, as supplements may have pharmacological effects not captured in standard drug interaction databases." [13]

What Drug Interaction Databases Currently Say

Standard drug interaction databases (Lexicomp, Micromedex, Drugs.com) do not list NMN or NR as interacting with trazodone, because neither compound is classified as a pharmaceutical drug and neither has been evaluated in formal DDI studies. This absence of a listed interaction is not the same as confirmed safety. It reflects a data gap.

The FDA does not require supplement manufacturers to conduct drug interaction studies before marketing. The burden of discovering interactions falls on post-market pharmacovigilance, case reports, and mechanistic inference, which is exactly the evidence base available here.

Summary of the Evidence Grade

| Domain | Evidence Level | Direction | |---|---|---| | Pharmacokinetic (CYP) interaction | Preclinical; no human DDI data | No interaction expected | | Sedation overlap | Mechanistic inference | Low risk; time doses apart | | Serotonin pathway (kynurenine) | Pathway biology; no clinical data | Theoretical concern | | SIRT1-MAO-A serotonin effect | Rodent data only | Unknown in humans | | Circadian/sleep interaction | One human NR trial (N=24) | Possible; not quantified | | Falls risk in older adults | Trazodone Beers Criteria data | Monitor in age 65+ |

The overall interaction severity is best classified as low-to-moderate theoretical, requiring timing awareness and routine monitoring rather than contraindication.